Close

Form 8-K BriaCell Therapeutics For: Jun 14

June 14, 2024 9:12 PM EDT
false 0001610820 A1 0001610820 2024-06-14 2024-06-14 0001610820 BCTX:CommonSharesNoParValueMember 2024-06-14 2024-06-14 0001610820 BCTX:WarrantsToPurchaseCommonSharesNoParValueMember 2024-06-14 2024-06-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): June 14, 2024

 

BRIACELL THERAPEUTICS CORP.

 

(Exact name of registrant as specified in its charter)

 

British Columbia   47-1099599

(State or other jurisdiction

of incorporation or organization)

 

(I.R.S. Employer

Identification No.)

     

Suite 300 - 235 15th Street

West Vancouver, BC V7T 2X1

  V7T 2X1
(Address of principal executive offices)   (Zip Code)

 

(604) 921-1810

(Registrant’s telephone number, including area code)

 

Commission File No. 001-40101

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered under Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Shares, no par value   BCTX   The Nasdaq Stock Market LLC
Warrants to purchase common shares, no par value   BCTXW   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

 

 

Item 7.01 Regulation FD Disclosure.

 

On June 14, 2024, BriaPro Therapeutics Corp., a two-third (2/3) owned subsidiary of BriaCell Therapeutics Corp. (the “Company”), filed its unaudited condensed interim financial statements and management’s discussion and analysis for the three and nine months ended April 30, 2024, with the British Columbia Securities Commission and Alberta Securities Commission. A copy of the condensed interim financial statements and management’s discussion and analysis for the for the three and nine month periods ended April 30, 2024 are included as Exhibit 99.1 and Exhibit 99.2 to this Current Report on Form 8-K and are incorporated herein by reference.

 

The information furnished pursuant to this Item 7.01, including Exhibit 99.1 and Exhibit 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933 (the “Securities Act”) or the Exchange Act, regardless of any general incorporation language in such filings.

 

Item 9.01 Condensed interim financial statements and Exhibits

 

EXHIBIT INDEX

 

Exhibit No.    
99.1   BriaPro Therapeutics Corp. Unaudited Condensed Interim Financial Statements for the three and nine month period ended April 30, 2024.
99.2   BriaPro Therapeutics Corp. Management’s Discussion and Analysis for the three and nine month periods ended April 30, 2024.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  BRIACELL THERAPEUTICS CORP.
   
  /s/ William V. Williams
June 14, 2024 William V. Williams
  President and Chief Executive Officer

 

 

ATTACHMENTS / EXHIBITS

ex99-1.htm

ex99-2.htm

XBRL SCHEMA FILE

XBRL DEFINITION FILE

XBRL LABEL FILE

XBRL PRESENTATION FILE

IDEA: R1.htm

IDEA: Financial_Report.xlsx

IDEA: FilingSummary.xml

IDEA: MetaLinks.json

IDEA: form8-k_htm.xml



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

SEC Filings